Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study -

Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study
Information type: Randomised controlled trials
Source: Pain
Specialities: Anaesthesia and pain | Gastrointestinal disorders
Summary
RCT (n=623) found fewer treatment emergent side effects with naldemedine vs placebo after 52 weeks (68.4% vs 72.1%, difference -3.6%, 95% CI -8.7 to -1.5). Iimprovements in overall constipation-related symptoms was observed with naldemedine vs placebo at all time points (P≤ 0.000
UKMi comment
Naldemedine is a peripherally-selective μ-opioid receptor antagonist. A market authorisation application for use in Europe is currently under review
Related links: